Where can I buy Selinisol targeted drug?

Selinexor (Selinexor) is an oral selective inhibitor of nuclear export (SINE) compound that covalently binds to and inactivates XPO1, causing TSP to accumulate in the nucleus, reducing oncoprotein translation, enhancing glucocorticoid receptor signaling, and inducing cell cycle arrest, ultimately leading to multiple myeloma (MM and other malignant tumors) cell death, but not normal cell death.

In the phase 2b STORM study of patients with refractory MM in three categories (proteasome inhibitors, immunomodulators and daratumumab), the overall response rate (ORR) of selinesol combined with dexamethasone was 26.2%, supporting the approval of selinesol in the United States. Selinisol continues to be evaluated in early treatment regimens (dose once or twice weekly) and combination regimens. Preclinical data show that selinesol has synergistic effects with multiple anti-MM drugs. In a phase 3 trial, the combination of once-weekly (QW) selinisol with QW bortezomib plus low-dose dexamethasone showed higher progression-free survival (PFS) and ORR, a trend toward decreased mortality, and significantly less peripheral neuropathy compared with standard twice-weekly (BIW) bortezomib.

The original drug Seleniso has been launched in China and is included in medical insurance. Patients who meet the indications can use medical insurance to purchase it. Patients who do not meet the conditions can only purchase it at their own expense. This drug may be sold in domestic hospitals or pharmacies. Currently, Seleniso original drug or generic drugs are also sold overseas, and the ingredients of both drugs are the same. For patients, when choosing to purchase selinesol, in addition to considering the efficacy of the drug itself, they also need to weigh its price factor. Therefore, patients should choose the source carefully when purchasing and make decisions under the guidance of a doctor.